Business combination creates 5th largest generics business in the US

8 May 2018

Anmeal and Impax create diversified pharmaceutical company.

Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have completed their business combination to form Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"). As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the US, with a growing, high-margin specialty franchise.

Business combination creates 5th largest generics business in the US

Shares of Impax ceased trading on the NASDAQ stock exchange on 4 May 2018. Amneal will begin trading today on the New York Stock Exchange (NYSE) under the ticker "AMRX". Pursuant to the business combination agreement, each share of Impax common stock was converted into the right to receive one share of Amneal Class A common stock.

"We are very excited for the future of Amneal, and strongly believe that with our team, differentiated product portfolio, extensive R&D and manufacturing infrastructure and expertise, Amneal is well positioned to become an industry leader," said Chirag Patel and Chintu Patel, Co-Founders and Co-Chairmen of Amneal. "We are very proud of the Company we have built and look forward to Amneal's continued success under Rob Stewart's leadership."

Robert Stewart, President and CEO of Amneal, said: "As we enter our next stage of growth, we look forward to implementing our integration plans and quickly starting to realize the many benefits of this combination. We will promptly begin to leverage our enhanced product portfolio to fuel organic growth while capturing numerous synergies to unlock value and generate strong cash flow to support the rapid repayment of debt and further investment in growth opportunities."

The Company expects to benefit from its expanded product portfolio, differentiated pipeline and cost-efficient global manufacturing and development capabilities in nearly all dosage forms. Amneal expects to generate annual double-digit revenue and adjusted EPS growth and to achieve annual cost synergies of approximately $200 million within 3 years.

"This is a truly transformative combination that firmly establishes Amneal as an industry leader, with high-value generic product pipelines and a growing specialty business," said Paul Bisaro, Executive Chairman of Amneal. "With our combined resources, we are well-positioned to execute our plans to bring high-quality, affordable medicines to patients and generate long-term returns for our shareholders."

Review of the Strategic and Financial Benefits of the Combination

  • The Company currently has a generics portfolio with more than 200 differentiated product families marketed in nearly all dosage forms and holds a number one or number two position in a significant number of its marketed products, and has a growing specialty franchise targeting CNS disorders and anti-parasitic infections.
  • The generic products pipeline is currently one of the largest in the US, including approximately 149 ANDAs filed at the FDA and 135 projects in active stages of development, with nearly half of all pipeline products exclusive first-to-file, first-to-market or other high-value opportunities with three or fewer competitors estimated at the time of launch. In addition, the Company has a foundation for commercial entry into biosimilars through in-licensed products in various stages of development.
  • The Company is committed to ongoing investments in R&D with an expected annual investment of approximately 10% of net revenues, with a focus on the strategic development of high-value products within generics and specialty pharmaceuticals. The Company has an extensive, diversified global supply chain supporting capabilities across nearly all dosage forms including solid oral dose, softgels, injectables, topicals, transdermals, inhalation, complex molecules and drug-device combinations, with R&D and manufacturing sites in the US, India and Ireland.
  • The Company expects to generate annual double-digit growth in net revenue, adjusted EBITDA and adjusted EPS over the next 3 years.
  • The Company expects to achieve significant annual cost saving opportunities of approximately $200 million within 3 years. The majority of the savings will result from the complementary nature of the companies' combined operations as well as margin-enhancing product transfer opportunities.
  • Read More

    Related news

    Allergan to establish R&D presence in Cambridge, Massachusetts

    Allergan to establish R&D presence in Cambridge, Massachusetts

    10 Jan 2019

    The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

    Read more 
    Expedeon signs supply and license agreement for is Lightning-Link technology

    Expedeon signs supply and license agreement for is Lightning-Link technology

    9 Jan 2019

    The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

    Read more 
    Lilly to bag Loxo Oncology for $8 billion

    Lilly to bag Loxo Oncology for $8 billion

    8 Jan 2019

    Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

    Read more 
    Catalent to double its commercial biomanufacturing capacity

    Catalent to double its commercial biomanufacturing capacity

    7 Jan 2019

    The $200-million expansion will support customers’ development programs and commercial launches.

    Read more 
    BMS and Celgene merge to create premier innovative biopharma company

    BMS and Celgene merge to create premier innovative biopharma company

    3 Jan 2019

    Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

    Read more 
    Cambrex completes acquisition of Avista Pharma Solutions

    Cambrex completes acquisition of Avista Pharma Solutions

    2 Jan 2019

    Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

    Read more 
    Novartis offers to acquire CellforCure

    Novartis offers to acquire CellforCure

    1 Jan 2019

    Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

    Read more 
    BMS receives offer from Taisho to purchase UPSA

    BMS receives offer from Taisho to purchase UPSA

    30 Dec 2018

    The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

    Read more 
    Recipharm to potentially end operations in Ashton-under-Lyne facility

    Recipharm to potentially end operations in Ashton-under-Lyne facility

    24 Dec 2018

    The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

    Read more 
    An increased risk of a hard or ‘no deal Brexit?

    An increased risk of a hard or ‘no deal Brexit?

    24 Dec 2018

    A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

    Read more